1450 ET - Americans are struggling to get their hands on branded GLP-1 medications, a hormone that helps regulate blood sugar, appetite, and digestion. Him and Hers, a health and wellness company, said that nearly 80,000 people have reported they can't get access to the drug, especially those in states where obesity is higher. To address this, Him & Hers introduced a GLP-1 supply tracker, allowing users to share their experiences and push for better access. This move could support the company's case for compounded versions of the drug, which the FDA is reviewing. Shares rise 3.7% to $27.67. (kailyn.rhone@wsj.com; @onlykailyn)
(END) Dow Jones Newswires
November 13, 2024 14:50 ET (19:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.